Basilea gibt positive Topline-Ergebnisse aus Phase-2-Studie FIDES-01 mit Derazantinib bei Patienten mit Gallengangkrebs (iCCA) und Fusionen des FGFR2-Gens bekannt

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition